All News

Olga Petryna Tweet
DrPetryna
#abst0129 #acr22 @rheumnow analysis 6 Euro studies of active RA, PsA, axSpA &secondary failure of TNFαi showed golimumab to be effective 2nd-line Rx. GLM show improvement in Dis activity, QoL& high retention( 2/3 pts on Rx after 12mo). https://t.co/6OeKwJpqQp
David Liew Tweet
drdavidliew
Genicular nerve block for knee OA - exciting short-term symptomatic option, great Australian work on the Ignite stage. Looking forward to seeing more! ABST1892 Shanahan et al @Flinders #ACR22 @RheumNow https://t.co/ssYoXj4wjg
Eric Dein Tweet
ericdeinmd
Ab0373 #ACR22 SpA-U @ChristianaSiero: 42 pts w/ SpA-r uveitis, 190 attacks Uveitis more severe: smoking, axial & peripheral involvement, BASDAI>4, HLA-B27+, female, CRP elevation, h/o bilateral ocular involvement Less severe: shorter disease evolution, nml vit D @Rheumnow
TheDaoIndex Tweet
KDAO2011
Important! Abst#2054 A Novel Treatment Response Measure (TRM) for SLE Clinical Trials is being developed, an international collaboration by clinical-academics, regulatory experts, pt reps, & industry. It will impact how clinical trials will be designed. #ACRbest @rheumnow #ACR22
Janet Pope Tweet
Janetbirdope
Be careful what you look for? Serum from 32 ACPA+ Pts and 30 ACPA neg all w #rheumatoidarthritis had multiplexed Ab- screening microarray w 1600+ antibodies. Novel Abs were identified in each group vs healthy controls. What does this mean? #ACR22 abst#0256 @RheumNow @ACRheum https://t.co/mqL8kuUkxY
Olga Petryna Tweet
DrPetryna
#ACR22 @RheumNow how do you approach treatment choices for your PsA pts on TNF inhibitors after first TNFi failure?
Robert B Chao, MD Tweet
doctorRBC
Large Korean study on risk of infections in ankylosing spondylitis patients receiving biologics. Infection incidence risk 26 events/1000 PY Resp infection most common, 2nd zoster Heart disease, high DA, DM, current bDMARD use = risk factors Abs#0372 @RheumNow #ACR22
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#ACR22 Abstr#1205. Are both mRNA vaccine Pfizer or Moderna equivocal in preventing breakthrough infection in fully vaccinated patients with SARDs? @zach_wallace_md showed comparable effectiveness between the two. We can promote whichever brands to our patients @RheumNow https://t.co/yhjxNE8pr2
Eric Dein Tweet
ericdeinmd
Ab0374 #ACR22 BASDAI during pregnancy: 50 pregnant women w/ AS vs controls AUC for BASDAI in 1st trimester: 0.74, max value for morning stiffness severity (0.9) & duration (0.8) In 2nd and 3rd trimester: AUC for fatigue and back pain <0.5, morning stiffness remains 0.8 @RheumNow https://t.co/ZQyB37dDxX
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×